Ursodeoxycholic Acid (UDCA) and Ademetionine (SAMe) in Liver Disease

1. Ursodeoxycholic Acid (UDCA / Ursodiol)

What it is

Mechanisms of Action

• Chronic administration makes UDCA the predominant bile acid (up to 40-60% of the pool)
• Hydrophobic bile acids (e.g., chenodeoxycholic acid, deoxycholic acid) are detergent-like and destroy cell membranes; UDCA is far less membrane-damaging
• Inhibits intestinal cholesterol absorption and reduces its secretion into bile, decreasing biliary cholesterol saturation - this is how it dissolves cholesterol gallstones

• Protects hepatocytes and cholangiocytes (bile duct cells) from bile acid-induced damage
• Hydrophobic bile acids generate reactive oxygen species (ROS) that trigger inflammation and cell death; UDCA blocks this process
• Prevents bile acid-induced apoptosis via stabilization of mitochondrial membranes

• Stimulates hepatocellular and biliary ductular secretion
• Upregulates transport proteins (e.g., BSEP, MRP2) on the bile canalicular membrane that export bile acids out of hepatocytes
• This enhanced secretion helps flush out retained toxic bile in cholestatic conditions

• Reduces HLA class I expression on hepatocytes (which reduces immune-mediated killing)
• Reduces cytokine-driven inflammation in the portal tracts
• This is particularly relevant in autoimmune liver disease (PBC)

• Inhibits farnesoid X receptor (FXR) in the intestine, which modulates bile acid synthesis feedback and accelerates bile enterohepatic circulation

Key Indications

Dose

• PBC: 13-15 mg/kg/day in 2-3 divided doses (this is the well-validated dose; underdosing is common in practice)
• ICP: 300 mg twice daily (or 10-15 mg/kg/day)

2. Ademetionine (S-Adenosylmethionine / SAMe)

What it is

Mechanisms of Action

• SAMe donates its methyl group to hundreds of substrates including DNA, RNA, histones, proteins, phospholipids, and neurotransmitters
• This supports cell membrane stability (via phosphatidylcholine synthesis), epigenetic regulation, and hepatocellular integrity
• In alcoholic liver disease, disrupted methylation leads to global DNA hypomethylation and impaired gene regulation

• SAMe feeds the transsulfuration pathway: SAMe → homocysteine → cysteine → glutathione
• Glutathione is the liver's primary antioxidant, neutralizing ROS and reactive metabolites
• In chronic liver disease, alcohol use, and cholestasis, hepatic GSH is severely depleted
• Supplementing SAMe directly replenishes glutathione stores, protecting hepatocytes from oxidative damage
• This is especially critical in alcoholic liver disease and drug-induced liver injury (DILI)

• Decarboxylated SAMe is a precursor for spermidine and spermine (polyamines)
• Polyamines regulate cell proliferation, hepatocyte regeneration, and DNA stabilization
• Important for liver regeneration and repair

• Reduces pro-inflammatory cytokine expression (e.g., TNF-α)
• Attenuates activation of hepatic stellate cells, reducing collagen deposition and fibrosis
• Anti-apoptotic on hepatocytes

• SAMe deficiency impairs mitochondrial oxidative phosphorylation
• Supplementation restores mitochondrial function, reducing ROS production

Key Indications

Dose

• Standard: 500-1000 mg/day IV or oral
• Some studies suggest higher doses (1600 mg/day) may be more effective for cholestasis

Why They Are Often Used Together

• UDCA primarily tackles the bile acid toxicity from outside the hepatocyte (extracellular/membrane mechanism)
• SAMe primarily protects the hepatocyte from within by replenishing glutathione and methyl donors
• They have synergistic hepatoprotection: one reduces bile acid damage, the other boosts the cell's antioxidant defenses
• Clinical trials show combined use achieves 96.5% clinical efficacy vs 78.9% with SAMe alone for cholestatic liver disease (Int J Clin Exp Med, 2021)
• Both are used together in intrahepatic cholestasis of pregnancy, with randomized trial evidence supporting the combination

Summary Table

Sources: Sleisenger & Fordtran's Gastrointestinal and Liver Disease; Goldman-Cecil Medicine; StatPearls - UDCA (NIH); PMC SAMe in cholestasis

ABG Interpretation - Patient SATPAL (14/07/2026)

Values at a Glance

Step-by-Step ABG Interpretation

1. Primary Disorder

• pH 7.46 → Alkalosis
• pCO2 30 mmHg → Low → this IS the cause of the alkalosis
• Primary Respiratory Alkalosis

2. Metabolic Compensation

HCO3 = 24 - 5 × (40 - pCO2)/10 = 24 - 5 × 1 = 19-20 mmol/L (chronic) For acute: 24 - 2 × (40 - 30)/10 = 24 - 2 = 22 mmol/L

3. Oxygenation

• pO2 169 mmHg with SO2 100% → Patient is on supplemental oxygen (FiO2 likely ~35-40%)

Critical Findings - The Electrolytes Are the Emergency

🔴 Sodium: 122 mmol/L - SEVERE HYPONATREMIA

• Normal: 135-145 mmol/L
• 13 mmol/L below lower limit - this is a medical emergency
• Symptoms expected: nausea, headache, confusion, seizures, cerebral edema
• Requires urgent investigation for cause (SIADH, cardiac failure, cirrhosis, hypothyroidism, etc.)
• Correction must be cautious - no faster than 6-8 mmol/L in 24 hours to avoid osmotic demyelination syndrome (ODS/CPM)

🔴 Ionized Calcium: 0.66 mmol/L - SEVERE HYPOCALCEMIA

• Normal: 1.12-1.32 mmol/L
• Less than half of the lower normal limit
• Risk of: tetany, laryngospasm, seizures, cardiac arrhythmias, prolonged QT
• Requires urgent IV calcium replacement

⚠️ Potassium: 3.2 mmol/L - Hypokalemia

• Mild but combined with hypocalcemia increases arrhythmia risk
• The respiratory alkalosis itself shifts K+ into cells, so true total body K+ deficit may be greater

⚠️ Glucose: 171 mg/dL

• Mildly elevated; patient may be diabetic or stress hyperglycemia

Clinical Interpretation Summary

• Hyperventilation due to pain, anxiety, or neurological disturbance (possibly driven by the hypocalcemia itself - hypocalcemia causes neuromuscular excitability and tetany leading to hyperventilation)
• Sepsis, liver failure, CNS lesion
• Hypoxia (though pO2 is high on O2)

1. Severe hyponatremia (122) - life-threatening, risk of brain herniation
2. Severe hypocalcemia (0.66) - life-threatening, risk of cardiac arrhythmia and laryngospasm
3. Hypokalemia (3.2) - compounding arrhythmia risk

Immediate Management Priorities

1. IV Calcium gluconate 10 mL of 10% solution slowly IV - urgent for ionized Ca 0.66
2. Identify and treat cause of hyponatremia - check serum osmolality, urine Na, urine osmolality, thyroid, cortisol, check for SIADH
3. Controlled Na correction - hypertonic saline (3%) only if symptomatic (seizures, coma); otherwise fluid restrict or treat underlying cause
4. Correct hypokalemia - KCl replacement (oral or IV)
5. ECG monitoring - given hypocalcemia + hypokalemia
6. Check Mg2+ - hypomagnesemia often coexists with hypocalcemia and prevents correction
7. Address the cause of hyperventilation - if tetany-driven, calcium correction will help

⚠️ This ABG represents a multi-electrolyte emergency. The patient needs close monitoring in a high-dependency or ICU setting.